Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.
10.3349/ymj.2017.58.5.959
- Author:
Jae Hyuk CHOI
1
;
Jung Rae CHO
;
Sang Min PARK
;
Kunal Bikram SHAHA
;
Floyd PIERRES
;
Tserendavaa SUMIYA
;
Kwang Jin CHUN
;
Min Kyung KANG
;
Seonghoon CHOI
;
Namho LEE
Author Information
1. Division of Cardiology, Hangang Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Antiplatelet therapy;
left ventricular function;
acute myocardial infarction
- MeSH:
Aspirin;
Humans;
Multivariate Analysis;
Myocardial Infarction*;
Percutaneous Coronary Intervention;
Retrospective Studies*;
Serotonin;
Standard of Care;
Stents;
Thrombosis;
Ventricular Function, Left
- From:Yonsei Medical Journal
2017;58(5):959-967
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this study was to assess the potential benefit of a 5-hydroxytryptamine receptor antagonist, sarpogrelate-based triple antiplatelet therapy (TAPT) in comparison with dual antiplatelet therapy (DAPT) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). MATERIALS AND METHODS: 119 patients of STEMI were retrospectively assessed. All patients received aspirin and clopidogrel per standard of care. Among them, 53 patients received an additional loading dose of sarpogrelate and a maintenance dose for 6 months post-PCI (TAPT group), while others did not (DAPT group). RESULTS: The rates of complete ST-segment resolution at 30 minutes post-PCI and post-procedural thrombolysis in myocardial infarction flow were not significantly different between the two groups (52.8% vs. 48.5%, p=0.200; 92.5% vs. 89.4%, p=0.080). In addition, no significant differences were observed between the two groups with regard to 30-day and 12-month clinical outcomes (cardiac death, myocardial infarction, stent thrombosis, target vessel revascularization, and severe bleeding). Meanwhile, improvement in left ventricular (LV) systolic function was observed in the TAPT group [ΔLV ejection fraction (LVEF)=17.1±9.4%, p<0.001; Δglobal longitudinal strain (GLS)=−9.4±4.2% , p<0.001] at 6 months, whereas it was not in the DAPT group (ΔLVEF= 8.8±6.5%, p=0.090; ΔGLS=−4.6±3.4%, p=0.106). In multivariate analyses, TAPT was an independent predictor for LV functional recovery (odds ratio, 2.61; 95% confidence interval, 1.16–5.87; p=0.003). CONCLUSION: Sarpogrelate-based TAPT improved LV systolic function at 6 months in STEMI patients undergoing primary PCI.
